We report three cases of spontaneous intracranial hemorrhage in patients who were initially hospitalized at our tertiary care center in Washington, DC with symptoms of COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed in all three patients, who were critically ill, requiring intubation and ventilatory support. During their protracted hospitalizations, subsequent imaging disclosed intracranial hemorrhages, including intracerebral and subarachnoid hemorrhages, in the context of anticoagulation and coagulopathy.

Our first patient was a 57-year-old woman with past medical history of hypertension, obesity, sleep apnea, and asthma who presented to our emergency department (ED) with shortness of breath and fever. After testing positive for SARS-CoV-2, she was initially admitted to the floor and subsequently escalated to the intensive care unit (ICU) and intubated for hypoxic respiratory failure. She developed acute renal insufficiency, requiring continuous veno-venous hemofiltration under coverage of a heparin drip. Following two weeks of mechanical ventilation, a computed tomography (CT) scan of the head was performed given persistent encephalopathy, revealing a subacute lobar right frontal intracerebral hemorrhage (ICH) **(** [Figure 1](#f0005){ref-type="fig"} **A)**. No coagulation or platelet dyscrasias were uncovered. Repeat CT imaging was stable, and following negative PCR testing for SARS-CoV-2, she was able to undergo contrasted magnetic resonance imaging (MRI), which did not disclosed an underlying pathology for the original ICH and revealed interval development of ICH in the left frontal lobe, despite being off heparization at that time **(** [Figure 1](#f0005){ref-type="fig"} **B-C)**. Interestingly, it also revealed significant inflammation of the sphenoid sinus -- a putative mechanism for neuro-invasion by the virus **(** [Figure 1](#f0005){ref-type="fig"} **D)**. The patient was subsequently discharged to an acute rehabilitation facility one week later.Figure 1**A:** Axial computed tomography (CT) of the head demonstrating a 3.5 x 3.4 x 3.2 cm acute intraparenchymal hematoma with inferior frontal midline shift. **B,C:** Axial magnetic resonance imaging (MRI) gradient echo (GRE) sequence demonstrating stable 3.2 cm right frontal intraparenchymal hematoma (B) with additional 0.6 cm left frontal intraparenchymal hematoma (C). **D:** Sagittal post-contrast T1 MRI with evidence of inflammation in the sphenoid sinus, a possible conduit for neuro-invasion by the virus. **E, F:** Axial (E) and coronal (F) non-contrast CT head demonstrating massive subarachnoid hemorrhage distributed throughout the basal cisterns with effacement of normal sulcal-gyri pattern. **G,H:** Axial (G) and sagittal (H) non-contrast CT head demonstrating a 2.2 x 2.2 cm intraparenchymal hemorrhage with surrounding hypodensity, suspicious for hemorrhagic transformation of a right-sided posterior cerebral artery (PCA) infarction.

The second patient is a 54-year-old female with past medical history of hypertension, obesity, and bilateral mastectomy in 2016 for BRCA2 mutant breast cancer who presented to our ED with four days of myalgia and fever. After testing positive for SARS-CoV-2, she was discharged to home, but was admitted two days later with dyspnea and hypoxia necessitating mechanical ventilation. She continued to deteriorate, entering vasodilatory shock requiring vasopressors and epoprostenol treatment with prone positioning. She had a transient thrombocytopenia and was placed on a heparin drip for thromboembolic protection. At 24 hours following cessation of heparin drip, at one week post-intubation, the patient developed dilated and non-reactive pupils on hourly neurologic checks and CT images of the head disclosed diffuse subarachnoid hemorrhage with intraventricular extension and sulcal effacement **(** [Figure 1](#f0005){ref-type="fig"} **E-F)**. She progressed to brain death and expired due to asystole four days later.[Table 1.](#t0005){ref-type="table"} Table 1Clinical Characteristics of Three COVID+ Patients who Developed Intracranial Hemorrhages**Case 1Case 2Case 3Age - years**575471**Gender**FemaleFemaleMale**Medical History**ObesitySleep ApneaAsthmaHypertensionBilateral Mastectomy (BRCA2 mutant breast cancer)HypertensionType II Diabetes MellitusChronic Kidney DiseaseB-Cell Lymphoma (In Remission)**Relevant Medications**Aspirin 81mgAspirin 81 mgPlacebo vs SarilumabEpoprostenolDesmopressinN/A**Presenting COVID Symptoms**Shortness of BreathFeverBody AchesFeverHypoxiaShortness of BreathDizziness**Hospital Stay Prior to ICH - days**20820**Duration of Intubation Prior to ICH - days**18815**Prone Positioning**+++**Other Critical Care Needs**VasopressorsContinuous Veno-Venous HemofiltrationVasopressorsVasopressors**Anticoagulation (Duration)**Heparin drip (6 days)Heparin drip (30 hours)N/A**Symptom Prompting Head Imaging**Persistent EncephalopathyFixed and Dilated PupilsPersistent Encephalopathy**Type and location of ICH**Right Frontal Lobar Intracerebral HemorrhageDiffuse Subarachnoid HemorrhageRight PCA distribution infarctwith hemorrhagic conversion**Imaging Studies Performed**CT and MRICT and Nuclear Medicine StudyCT**Laboratory Values - At Presentation / At Time of ICH / Minimum-MaximumWhite Blood Cell Count - per mm3**10,700 / 24,800 / 8,800-91,0008,300 / 17,300 / 5,200-18,20010,200 / 9,300 / 5,300-18,600**Platelet Count - per mm3**200,000 / 181,000 / 159,00-506,000135,000 / 123,000 / 17,000-137,000207,000 / 354,000 / 64,000-360,000**Prothrombin Time - seconds**13.2 / 13.9 / 13.2-15.713.0 / 14.5 / 13.0-14.813.5 / 20.3 / 13.2-20.3**Activated Partial-Thromboplastin Time - seconds**33.2 / 20.8 / 20.8-40.925.1 / 48.2 / 25.1-48.2N/A / 57.3 / 57.3-65.7**International Normalized Ratio**1.0 / 1.1 / 1.0-1.21.0 / 1.1 / 1.0-1.21.0 / 1.7 / 1.0-1.7**Anti-Xa - IU/mL**N/A / N/A / 0.23-1.10N/A / 0.26 / 0.97-1.10N/A**Fibrinogen - mg/dL**N/A / 638 / 382-1,214630 / 308 / 308-788672 / 1,276 / 672-1,276**D-dimer - mcg/mL**1.06 / 14.08 / 1.06-18.630.52 / 13.79 / 0.52-20.001.44 / 9.55 / 1.44-9.88**Outcome**Acute rehabilitationCerebral circulatory arrest confirmed by nuclear medicine studyPalliative extubation[^1]

The third patient is a 71-year-old gentleman with past medical history of hypertension, type II diabetes, chronic kidney disease, and B-cell lymphoma in remission who presented to the ED with acute onset shortness of breath and dizziness. After testing positive for SARS-CoV-2, the patient was admitted, progressing from a 15-liter supplement oxygen requirement to intubation, prone positioning, and vasopressor support within 5 days of admission. At two weeks post-intubation, persistent encephalopathy promoted a surveillance head CT, which disclosed a right occipital ICH with surrounding edema suggestive of hemorrhagic conversion of an infarct **(** [Figure 1](#f0005){ref-type="fig"} **G-H)**. D-dimer and fibrinogen were elevated to 3.2mcg/mL (normal range 0 -- 0.72mcg/mL) and 1,018mg/dL (normal range 213 -- 536mg/dL), respectively, indicating a hypercoagulable state. While international normalized ratio (INR) and platelet counts were within normal range prior to the hemorrhage, they subsequently became profoundly hypercoagulable and thrombocytopenic afterwards, suspicious for disseminated intravascular coagulation (DIC). While the ICH remained stable on repeat imaging, the patient ultimately succumbed to multi-system organ failure one week later.

These cases support the predisposition of COVID-19 patients to the development of intracranial hemorrhage during critical illness. The pathophysiology is unclear, but the tropism of SARS-CoV-2 to the endothelial lining of the cerebral vasculature via their angiotensin-converting enzyme (ACE) II receptors, remains a possibility[@b0005], [@b0010], and a recent pathology study *The Lancet* demonstrated the presence of virus particles within endothelial cells and an accumulation of inflammatory cells, leading to endothelial cell death.[@b0015] Furthermore, a recent Italian review of animal studies suggests a higher neuro-invasive property of SARS-CoV-2 compared to other coronaviruses.[@b0020] Zhou et al were able to detect SARS-CoV-2 RNA in human cerebrospinal fluid, and neurologic sequelae have been observed in an estimated 36% of COVID-19 patients.[@b0025], [@b0030], [@b0035] Postmortem brain studies have also shown direct invasion of neurons and glial cells.[@b0040], [@b0045] Several studies have suggested a pro-thrombotic state in these patients, possibly related to antiphospholipid antibodies, which may lead to ischemic complications related to occlusion of the cerebral vasculature.[@b0050], [@b0055], [@b0060], [@b0065], [@b0070], [@b0075] Additionally, numerous reports of ICH in COVID-19 have begun to accumulate in the literature.[@b0080], [@b0085], [@b0090], [@b0095], [@b0100] Collectively, these findings corroborate the possibility of direct cerebrovascular endothelial injury, vascular injury, and DIC leading to cerebral hemorrhagic events, exacerbated by concomitant anticoagulation therapy in two instances.

The ability to identify and treat these patients is hindered by the strict isolation and precautions mandated by COVID-19 infection. Given our findings, we advocate heightened vigilance for intracerebral hemorrhage events, and scanning when practicable, in COVID-19 patients which have prolonged ventilatory support and depressed neurologic examinations.
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